Condition: Long COVID · Post COVID-19 Condition · Post Acute Sequelae of COVID-19 · Sponsor: University Health Network, Toronto
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects. We conducted a pilot study assessing the open label use of re-breathing CO2 (using Hi-OxSR) twice a day for 14 days, for the treatment of post-COVID cognitive dysfunction. Significant improvements were found in multiple cognitive assessments using TestMyBrain cognitive tests and brain fog (MSNQ) and fatigue scores. This phase 2 clinical trial seeks to build on current findings to determine the optimal effective dose of treatment (i.e. length of use, oxygen concentration, without or without CO2 rebreathing) and the safety of using Hi-OxSR in this patient population.
This description comes directly from the study's public registry record.
suzanne Cohen · 1-866-673-2524 · reclaim@uhn.ca
Always discuss trial participation with your own doctor first.
| Kaye Edmonton Clinic | Edmonton, Alberta, Canada | Not Yet Recruiting |
| University Health Network | Toronto, Ontario, Canada | Recruiting |
| Centre Hospitalier Universitaire de Sherbrooke | Sherbrooke, Quebec, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06928506